Biolife Solutions (BLFS) EBITDA Margin (2010 - 2026)

Biolife Solutions (BLFS) has reported EBITDA Margin for 17 consecutive years, with 5.96% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 7476.0% year-over-year to 5.96% in Q2 2026; TTM through Jun 2026 was 2.9%, a 2302.0% increase from a year earlier, with the FY2025 full-year figure at 17.26%, down 1126.0% from the prior year.
• EBITDA Margin was 5.96% for Q2 2026 at Biolife Solutions, up from 0.1% in the prior quarter.
• Over five years, EBITDA Margin peaked at 7.17% in Q4 2025 and troughed at 218.96% in Q4 2022.
• A 5-year average of 44.62% and a median of 19.94% in 2022 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin slumped 17429 bps in 2022 and jumped 15254 bps in 2023, its largest moves.
• Over 5 years, EBITDA Margin stood at 218.96% in 2022, then soared by 43 bps to 125.43% in 2023, then jumped by 103 bps to 3.59% in 2024, then jumped by 100 bps to 7.17% in 2025, then declined by 17 bps to 5.96% in 2026.
• The last three EBITDA Margin figures came in at 5.96% (Q2 2026), 0.1% (Q1 2026), and 7.17% (Q4 2025), per Business Quant data.